BIO-TECHNE CORP shareholders Q3 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
SUSQUEHANNA INTERNATIONAL GROUP, LLP 39,800$2,709,1860.00%
First Horizon Advisors, Inc. 330$22,4620.00%
MACROVIEW INVESTMENT MANAGEMENT LLC 15$1,0220.00%
KEYBANK NATIONAL ASSOCIATION/OH 4,011$273,0260.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 282$19,1950.00%
WELLS FARGO & COMPANY/MN 56,470$3,843,9280.00%
J.P. Morgan Private Wealth Advisors LLC 5,997$408,1910.00%
Sutton Wealth Advisors Inc. 43$2,9270.00%
Robeco Institutional Asset Management B.V. 3,276$222,9980.00%
Concord Wealth Partners 84$5,7180.00%
UBS Group AG 28,301$1,926,4490.00%
Raymond James Financial Services Advisors, Inc. 4,354$296,3480.00%
Citadel Advisors 50,300$3,423,9210.00%
HARBOUR INVESTMENTS, INC. 324$22,0550.00%
Penserra Capital Management LLC 870$590.00%
BNP Paribas Asset Management Holding S.A. 6,621$4510.00%
CAPSTONE INVESTMENT ADVISORS, LLC 3,200$217,8240.00%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 5,577$379,6260.00%
Steward Financial Group LLC 33$20.00%
Harel Insurance Investments & Financial Services Ltd. 390$270.00%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.